SBRT for Bone Cancer

Recruiting in Palo Alto (17 mi)

Overseen by Tracy Balboni, MD MPH

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Dana-Farber Cancer Institute

No Placebo Group

Prior Safety Data

Approved in 4 Jurisdictions

Trial Summary

What is the purpose of this trial?

This research study is studying a form of radiation therapy called stereotactic body radiation therapy or SBRT as a possible treatment for Cancer that has spread to the spine or other bone

Eligibility Criteria

This trial is for adults over 18 with bone cancer that has spread to the spine or other bones, but not more than three places. They should be in good enough health to sign consent and have a life expectancy of over 3 months. Pregnant women, those with blood cancers, recent other cancers (except certain skin cancers and cervical cancer in situ), or who can't lie still for treatment are excluded.

Inclusion Criteria

I am 18 years old or older.

My cancer spread to bones is less than 6 cm and affects no more than 3 spine bones.

I haven't had any cancer except for skin cancer or cervical pre-cancer in the last 2 years.

Exclusion Criteria

I have received radiation therapy with a dose higher than 100 Gy2.

I am currently receiving treatment for my cancer that involves medication taken by mouth or injection.

I can't stay still for treatments even with medication for anxiety or pain.

Participant Groups

The study tests Stereotactic Body Radiation Therapy (SBRT) using a Stereotactic Linear Accelerator on patients with limited metastatic bone disease. It aims to see if this targeted radiation therapy is effective for treating small areas where cancer has spread to the bones.

Group I: Re-irradiation to Metastatic Disease Experimental Treatment 2 Interventions

Stereotactic Body Radiation Therapy (SBRT) to site(s) of disease occurring in the bone or spine * Treatments will be delivered on a dedicated stereotactic linear accelerator that includes onboard conebeamCT imaging and orthogonal 2D/3D matching with robotic couch top. * Dosage will be determined by physician

Group II: Oligometastatic Disease Experimental Treatment 2 Interventions

Stereotactic Body Radiation Therapy (SBRT)to up to 3 sites of disease occurring in the bone or spine * Treatments will be delivered on a dedicated stereotactic linear accelerator that includes onboard conebeamCT imaging and orthogonal 2D/3D matching with robotic couch top. * Dosage will be determined by physician

Stereotactic Body Radiation Therapy (SBRT) is already approved in United States, European Union, Canada, Japan for the following indications:

🇺🇸 Approved in United States as Stereotactic Body Radiation Therapy for:

• Prostate cancer
• Lung cancer
• Liver cancer
• Pancreatic cancer
• Spinal tumors

🇪🇺 Approved in European Union as Stereotactic Body Radiation Therapy for:

• Prostate cancer
• Lung cancer
• Liver cancer
• Pancreatic cancer
• Spinal tumors

🇨🇦 Approved in Canada as Stereotactic Body Radiation Therapy for:

• Prostate cancer
• Lung cancer
• Liver cancer
• Pancreatic cancer
• Spinal tumors

🇯🇵 Approved in Japan as Stereotactic Body Radiation Therapy for:

• Prostate cancer
• Lung cancer
• Liver cancer
• Pancreatic cancer
• Spinal tumors

Find a Clinic Near You

Research Locations Nearby Select from list below to view details:

Dana Farber Cancer Institute Boston, MA

Who Is Running the Clinical Trial?

Dana-Farber Cancer Institute Lead Sponsor

References